We explored in an immune-competent, aggressive GB preclinical model how using the direct mitigation of the tumour-based immune suppression microenvironment (PD-1/PD-L1 pathway blockade) either as monotherapy or in combination with TMZ, produced outstanding results, not achieved before with comparable treatments. The gene discussed is PDCD1; the disease is neoplasm.